Kedrion Biopharma received the Industry Innovation Award from the American National Organization for Rare Diseases.
The award went to RYPLAZIM, the world’s first US FDA-approved treatment for Type 1 Plasminogen Deficiency. The product was developed by Prometic, a subsidiary of Kedrion based in Laval, Canada.
The award was presented Sunday at the Rock & Roll Hall of Fame in Cleveland, Ohio, as part of the Rare Impact Awards, which NORD organizes annually to recognize individuals and organizations who have brought significant improvements to millions of Americans. affected by rare diseases.
To collect the prize Giorgio Masetti, VP, Kedrion US Regional Sales Director. “We thank NORD for this honor as well as for all the important work it does in support of those suffering from rare diseases and conditions. I would also like to offer a special thought to our colleagues at Prometic in Laval, Canada: it was their creativity, their hard work and their tenacity that made this therapy possible ”. Masetti continued: “Kedrion’s mission is to provide patients with treatments for rare diseases that give them hope. Those with Congenital Plasminogen Deficit have suffered for years without finding relief. Today we are proud to be able to provide him with this therapy ”.
The award was presented by Dr. Rebecca Bialas, mother of a child with PLGD-1. “I am so grateful to the people of Kedrion for embracing this cause and for all the amazing things they are doing! I can’t find the words to express my gratitude for what is happening, ”said Rebecca Bialas. “This treatment has given us hope for a future for our children and for all other patients affected by this disease.” Rebecca and her husband Ryan founded the Plasminogen Deficiency Foundation, whose mission is to promote the care and treatment of patients with Plasminogen Deficiency.
This award is the recognition of one of the founding moments in the history of Kedrion Biopharma. Paolo Marcucci, Executive Chairman of Kedrion, said: “From the beginning, we have been dedicated to the mission of providing relief to people suffering from rare and debilitating diseases and conditions. It is thanks to the generosity of donors that we have the opportunity to develop therapies that can change people’s lives. In this way we can offer a bridge between donors and patients, between despair and hope. About fifteen years ago we started specific research to develop a treatment for Plasminogen deficiency. Today we accept this award with great satisfaction “.
No related articles